Amendments to the Specification

The following page and line numbers refer to the published PCT application.

Please replace the paragraph at page 1, lines 3-9 with the following amended paragraph:

BACKGROUND OF THE INVENTION

The present invention relates to a combination comprising *N*-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, hereafter "Compound **(I)**", and a luteinizing hormone releasing hormone analogue (hereafter LHRH analogue). The present invention further relates to a combination comprising Compound **(I)** and a diphosphonic acid derivative (hereafter bisphosphonate) and a combination comprising Compound **(I)**, an LHRH analogue and a bisphosphonate.

Please replace the paragraph at page 4, lines 8-9 with the following amended paragraph:

BRIEF SUMMARY OF THE INVENTION.

Therefore according to the present invention, there is provided a combination, comprising Compound **(I)**, and an LHRH analogue.

Please replace the paragraph at page 4, lines 14-24 with the following amended paragraph:

DETAILED DESCRIPTION OF THE INVENTION.

Herein where the term "LHRH analogue" is used it is to be understood that this refers to any chemical compound, or a pharmaceutically acceptable salt thereof, including small molecules and peptides, which acts as an agonist or antagonist at the LHRH receptor, whether by an interaction with the LHRH binding site or by an allosteric mechanism, i.e. acts at a position on the LHRH receptor different to the LHRH binding site. In one aspect of the invention an "LHRH analogue" refers to an LHRH antagonist or a pharmaceutically acceptable salt thereof. In one aspect of the invention an "LHRH analogue" refers to an LHRH agonist or a pharmaceutically acceptable salt thereof. In a further aspect of the invention an "LHRH analogue" refers to a combination of an LHRH antagonist or a pharmaceutically acceptable salt thereof and an LHRH agonist or a pharmaceutically acceptable salt thereof.